DARA Biosciences — IPO Roadshow (March 2012)
25 slides from DARA Biosciences's IPO roadshow presentation, Mar 26, 2012
Slide 1: Investor Presentation March 2012
Filed Pursuant to Rule 433 Registration No. 333-179637 March 26, 2012 Investor PresentationMarch – 2012
Slide 2: Registration Statement
Registration Statement THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR
Slide 3: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not historical facts are forward-looking statements and are subject to certain risks and uncertainties. These statements are based on the current expectations, estimates, forecasts and projections regarding management’s beliefs and
Slide 4: Company Overview
Company Overview DARA BioSciences, Inc. (Nasdaq: DARA) is an oncology focused biopharmaceutical company uniquely covering the spectrum of oncology treatment and supportive care Treatment Soltamox®(liquid tamoxifen) FDA approved Gemcitabine ANDA preparation Other cytotoxics TBA KRN5500 (novel compoun
Slide 5: Pipeline
Pipeline Phase 3 or | Pre-clinical Phase 1 Phase 2 ANDA prep Filed Approved Additional oral liquid products under license discussions Fast Track status approved in 2011 Nasdaq:DARA Page 5
Slide 6: Management Team
Management Team Highlyexperienced management teamwithover100yearsof collective expertise Steve Gorlin Chairman – DARA founder, former director, and successful serial entrepreneur: Medicis Pharma (NYSE: MRX), EntreMed (Nasdaq:ENMD),Medivation(Nasdaq:MDVN),others;Boardmember– JohnsHopkinsAlliancefor S
Slide 7: Soltamox - Breast Cancer Overview
Soltamox® - Breast Cancer Overview nd Breast cancer is the leading 2 cause of mortality in women Soltamox® is the only oral liquid tamoxifen for the treatment of breast cancer approved by the FDA 2.6 million women in the US with a history of breast cancer Approximately 232,000 newly diagnosed each y
Slide 8: Soltamox Overview
Soltamox® Overview Soltamox will provide tamoxifen treated breast cancer patients needed a alternative to tablets Dysphagia (difficulty swallowing) occurs more frequently in Elderly patients Post-menopausal women Patients undergoing radiation Patients undergoing surgery Dysphagia is under-reported t
Slide 9: Soltamox Value
Soltamox® Value Soltamox will provide a solid base of revenue growth for DARA Approved as a 505(b)(2) Serve as a registration pathway for other oral liquid products Identical labeling to approved tamoxifen US Issued Patent Exclusivity until 2018 Branded Product Higher Pricing/no generic substitution
Slide 10: Commercial Strategy
Commercial Strategy Oncology is a niche specialty allowing DARA to efficiently deploy resources Oncologists 15,132 Radiation Medical Gynecology Hematology Oncology Oncology Oncology 4,822 4,320 5,364 441 Focus on top decile MDs Small dedicated sales team Supplement/partner with other specialty compa
Slide 11: Soltamox - Marketing and Sales Efforts
Soltamox® - Marketing and Sales Efforts Oncology is a niche specialty allowing DARA to efficiently deploy resources Marketing and sales efforts will focus on high decile oncologists who prescribe over 80% of tamoxifen scripts Education vs selling No need to “sell”tamoxifen Assist physicians to ident
Slide 12: Soltamox Summary
Soltamox® Summary Soltamox and other oral liquids are niche opportunities satisfying an unmet medical need Dysphagia is a relevant concern and issue in breast cancer patients Favorable competitive landscape Potential expanded market use Increase dysphagia awareness with physicians Cost savings to he
Slide 13: Bionect (LMW hyaluronic acid (HA))
Bionect® (LMW hyaluronic acid (HA)) Bionect® is a complementary and synergistic product with Soltamox® Prescription product-FDA cleared Radiation and oncology targets Many breast cancer patients receive radiation 90% develop dermatitis Expand usage to other cancers No upfront/outlay of expenses for
Slide 14: Injectable Sterile Cytotoxics - Anticipated Pipeline
Injectable Sterile Cytotoxics Anticipated – Pipeline DARA is pursuing development of standard of care injectable cytotoxics with combined US sales in excess of $5 billion Total US Regulatory Product / Sales, 2010 Clinical US Patent Patent Holder Use Approval Trade Name Studies Expiration ($ billion)
Slide 15: Sterile Injectable Cytotoxics
Sterile Injectable Cytotoxics Unique market dynamics indicate strong growth for sterile cytotoxic injectables Leading Still Likely cytotoxics Considered volume losing patent to be “gold increase protection standard” Less price Fewer Attractive erosion competitors margins Nasdaq:DARA Page 15
Slide 16: Sterile Injectable Cytotoxics
Sterile Injectable Cytotoxics Participation in lucrative sterile cytotoxic market will be efficient cost for DARA Lower development costs and risks FDA does not require clinical studies for sterile injectable ANDAs Partner (Uman) has proven ability to meet product specifications FDA inspected and ap
Slide 17: Strategic Partners
Strategic Partners Strategic partners are key to long-term growth Potential to develop/license a Rosemont US License range of oral to Soltamox liquid products. Exploit other ex US markets. Potential to develop/license US License to a range of Uman Gemcitabine sterile injectable cytotoxics No need fo
Slide 18: KRN5500 for Neuropathic Cancer Pain
KRN5500 for Neuropathic Cancer Pain Intravenous first-in-class, non-narcotic/non-opioid spicamycin-derived small molecule analgesic • 19-patient Phase 2a study • Double-blind, placebo-controlled • Multicenter, dose escalation design • Cancer patients with treatment-refractory pain • Most had chemoth
Slide 19: CIPN Market Opportunity is Significant
CIPN Market Opportunity is Significant Chemotherapy Induced Peripheral Neuropathy (CIPN) is prevalent and debilitating* Peripheral sensory nerves, arms and legs Numbness, tingling, allodynia (light touch or cold interpreted as severe pain) Uncertain mechanism Extremely common Platins -up to 74%; Tax
Slide 20: Further Development of KRN5500
Further Development of KRN5500 Strategic fit for DARA oncology/oncology support franchise Re-analysis of Phase 2 underway to confirm efficacy signal Potential orphan pathway opportunity Current vehicle contains organic solvents (safety and regulatory risks) Improved formulation underway; patent file
Slide 21: Out-Licensing Candidates
Out-Licensing Candidates PPAR pipeline licensed from Bayer DB-959 has completed Phase 1 development Non-TZD oral PPAR delta /gamma ( ) agonist Targeted for type 2 diabetes and dyslipidemia PK consistent with once/day dosing Tolerability equivalent to placebo in SAD/MAD clinical studies Further devel
Slide 22: 2012 Anticipated Key Events
2012 Anticipated Key Events 2Q –3Q Bionect®launch to radiation oncologists/oncologists Soltamox®launch Complete financing 2Q –4Q In-license/acquisition of marketed/near-term product Rosemont partnership expansion Uman partnership expansion New partnerships Nasdaq:DARA Page 22
Slide 23: Comparable Companies
Comparable Companies DARA has significant potential for value creation based upon comparable companies Access Pharmaceuticals, Inc. (OTCBB:ACCP) Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) Market Cap: $48M(1) Market Cap: $402M LTM Sales: $2M LTM Sales: $16M Revenue Multiple: 24.0x Revenue Multiple: 2
Slide 24: DARA Summary
DARA Summary DARA Biosciences has evolved into a fully integrated oncology focused specialty company with multiple opportunities for long-term, sustained growth Highly experienced management team Anticipated revenue generation in 2012 Soltamox® Bionect® Other marketed product Potential US developmen
Slide 25: Nasdaq:DARA www.DARAbio.com
Nasdaq:DARA www.DARAbio.com 8601 Six Forks Road Suite 160 | Raleigh, NC | 27615 | United States Phone: 919-872-5578Fax: 919-861-0239